Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis

J Gen Virol. 1999 Nov:80 ( Pt 11):2931-2936. doi: 10.1099/0022-1317-80-11-2931.

Abstract

Human papillomavirus (HPV) exists as more than 100 genotypes. It is not well-established whether the different HPV types interfere with infection or pathogenesis by each other. Possible interactions in cervical carcinogenesis between infection with the most common HPV types (6, 11, 16, 18 and 33) were studied in a seroepidemiological case- control study of 218 women with primary untreated cervical cancer and 219 healthy age-matched control women. As previously shown, HPV-16 seropositivity was associated with cervical cancer risk [odds ratio (OR), 2.39], but HPV-16 was not associated with cervical cancer risk among HPV-6 seropositive women (OR, 1.0). The relative excess risk due to interaction between HPV-6 and -16 was -2. 35 (95% confidence interval, -0.04 to -4.65), indicating significant antagonism. The results suggest that infection with HPV-6 may interfere with HPV-16-associated cervical carcinogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral / blood
  • Case-Control Studies
  • Female
  • Humans
  • Papillomaviridae / immunology*
  • Papillomavirus Infections / prevention & control*
  • Seroepidemiologic Studies
  • Tumor Virus Infections / prevention & control*
  • Uterine Cervical Neoplasms / prevention & control*
  • Uterine Cervical Neoplasms / virology

Substances

  • Antibodies, Viral